Expertise in
10
conditions

Dr. Anthony C. Evans

Oncology
MCHS Hospitals Inc.
1000 N Oak Ave, 
Marshfield, WI 
Accepting New Patients
Expertise in
10
conditions
MCHS Hospitals Inc.
1000 N Oak Ave, 
Marshfield, WI 

Overview

Anthony Evans is an Oncologist practicing medicine in Marshfield, Wisconsin.

Dr. Evans is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Endometrial Cancer, Malignant Mixed Mullerian Tumor, Vulvar Cancer, Hernia Surgery, and Bladder Reconstruction.

He is actively involved in clinical research, co-authoring 1 peer reviewed article and participating in 5 clinical trials. Dr. Evans is currently accepting new patients.

Specialties

Oncology

Licenses

Obstetrics & Gynecology in LA

Hospital Affiliations

Gundersen Lutheran Medical Center
Womans Hospital
Salem Health West Valley
Salem Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Louisiana Healthcare Connections
  • HMO
  • MANAGED MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

MCHS Hospitals Inc.
1000 N Oak Ave, Marshfield, WI 54449

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women With Recurrent, Persistent or Metastatic Endometrial Cancer. A Multi-Arm Trial for Women With Recurrent or Persistent Endometrial Cancer
A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women With Recurrent, Persistent or Metastatic Endometrial Cancer. A Multi-Arm Trial for Women With Recurrent or Persistent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug, Procedure, Biological
Study Phase: Phase 2
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Atezolizumab, Bevacizumab, Pegylated liposomal doxorubicin hydrochloride
Study Phase: Phase 2/Phase 3
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2026
Intervention Type: Drug, Procedure, Other
Study Drugs: Carboplatin, Cediranib Maleate, Gemcitabine, Gemcitabine Hydrochloride, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride
Study Phase: Phase 3
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
Enrollment Status: Active_not_recruiting
Publish Date: July 01, 2026
Intervention Type: Procedure, Drug, Other
Study Drugs: Cediranib, Cediranib Maleate, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan, Topotecan Hydrochloride
Study Phase: Phase 2/Phase 3
A Phase II Evaluation of Copanlisib (BAY 80-6946), a Selective Inhibitor of PI3KCA, in Patients With Persistent or Recurrent Endometrial Carcinoma Harboring PIK3CA Hotspot Mutations
A Phase II Evaluation of Copanlisib (BAY 80-6946), a Selective Inhibitor of PI3KCA, in Patients With Persistent or Recurrent Endometrial Carcinoma Harboring PIK3CA Hotspot Mutations
Enrollment Status: Completed
Publish Date: February 15, 2022
Intervention Type: Drug, Other
Study Drug: Copanlisib
Study Phase: Phase 2
View 4 Less Clinical Trials

1 Total Publications

Pre-operative assessment and post-operative outcomes of elderly women with gynecologic cancers, primary analysis of NRG CC-002: An NRG oncology group/gynecologic oncology group study.
Pre-operative assessment and post-operative outcomes of elderly women with gynecologic cancers, primary analysis of NRG CC-002: An NRG oncology group/gynecologic oncology group study.
Journal: Gynecologic oncology
Published: March 06, 2018
Similar Doctors
Expertise in
52
conditions
Expertise in
52
conditions
Referral may be required

Marshfield Medical Center-Weston Medical Offices-Cancer Care

3400 Ministry Pkwy, 
Weston, WI 
 (32.8 miles away)
715-393-1400
Languages Spoken:
English, Yoruba
See accepted insurances
Accepting New Patients
Offers Telehealth

Adedayo Onitilo is an Oncologist practicing medicine in Weston, Wisconsin. Dr. Onitilo is highly rated in 52 conditions, according to our data. His clinical expertise encompasses Neuroendocrine Tumor, Breast Cancer, Colorectal Cancer, Pancreaticoduodenectomy, and Gallbladder Removal. Dr. Onitilo is currently accepting new patients.

Expertise in
23
conditions
Expertise in
23
conditions
Referral may be required

Marshfield Medical Center-Marshfield Medical Offices Cancer Care

1000 N Oak Ave, 
Marshfield, WI 
 (0.1 miles away)
715-387-5416
Languages Spoken:
English, Twi
See accepted insurances
Accepting New Patients

Isaac Yeboah is an Oncologist practicing medicine in Marshfield, Wisconsin. Dr. Yeboah is highly rated in 23 conditions, according to our data. His clinical expertise encompasses Clear Cell Sarcoma, WT1-Related Wilms Tumor Syndromes, Angiosarcoma, Bone Marrow Aspiration, and Gastrostomy. Dr. Yeboah is currently accepting new patients.

Expertise in
12
conditions
Dr. Hamid Emamekhoo
Oncology | Hematology Oncology | Hematology
Expertise in
12
conditions
Dr. Hamid Emamekhoo
Oncology | Hematology Oncology | Hematology
Referral may be required

University Of Wisconsin Medical Foundation Inc

1040 Division St, 
Mauston, WI 
 (61.9 miles away)
608-847-7355
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Hamid Emamekhoo is an Oncologist and a Hematologist Oncology provider practicing medicine in Mauston, Wisconsin. Dr. Emamekhoo is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Renal Cell Carcinoma (RCC), Urothelial Cancer, Prostate Cancer, Nephrectomy, and Tissue Biopsy. Dr. Emamekhoo is currently accepting new patients.

Frequently Asked Questions about Dr. Anthony C. Evans

How do I make an appointment with Dr. Anthony C. Evans?

You can book an appointment with Dr. Anthony C. Evans by calling their office at 715-387-5161. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Anthony C. Evans a top-rated expert for Endometrial Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Anthony C. Evans is classified as an Advanced expert for Endometrial Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Anthony C. Evans specialize in?

While Dr. Anthony C. Evans is a Oncology, they have specific expertise in Endometrial Cancer, Malignant Mixed Mullerian Tumor, and Vulvar Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Anthony C. Evans participate in research or clinical trials?

Yes. Dr. Anthony C. Evans has published 1 articles and abstracts on conditions like Endometrial Cancer. You can view a list of Dr. Anthony C. Evans's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Anthony C. Evans accept my insurance?

Dr. Anthony C. Evans accepts most major insurance plans, including Aetna and Blue Cross Blue Shield. We recommend calling the office directly at 715-387-5161 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Evans's expertise for a condition
ConditionClose
      View All 10 Advanced Conditions
      View All 8 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile